Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2013

View Archived Issues

Dopamine D2 receptor PAMs for Parkinson's disease

Cancer Genetics launches FHACT test

US WorldMeds begins trial of Myobloc to treat sialorrhea

Collaboration to focus on 17-beta-HSD 1 inhibitor for endometriosis and estrogen-dependent cancers

RaQualia and Asahi Kasei Pharma sign joint research agreement

Phase III study of MLN-9702 for relapsed/refractory multiple myeloma opens to Japanese patients

Shionogi licenses pain products for Japan from Mundipharma

Recombinant tetravalent glycoprotein vaccine V-180 for dengue virus

Major role for rare heterozygous truncating mutations in autism etiology identified

Japanese researchers present novel peripheral blood lymphocyte-reducing agents

Carna Biosciences presents new BTK inhibitors

U.S. and Canadian team synthesizes novel PAR-4 antagonists for thromboembolism

Toleranzia discloses novel immunotolerizing fusion proteins for multiple sclerosis

Retrophin patents novel vitamin B5 prodrugs

Neuronascent Alzheimer's disease candidate advances to IND-enabling studies

AbbVie reports on first of six phase III studies of interferon-free, 12-week HCV regimen

Defibrotide receives European orphan drug designation for GVHD

Viriom expands licensing agreement with Roche for VM-1500

Clinical results for K-877, a novel PPAR-alpha receptor agonist, presented

Horizon Pharma to acquire U.S. rights to Vimovo

Consortium launches EPITARGET project focused on epileptogenesis and epilepsy

Project A.L.S. and Lilly team up on ALS research

Once-daily inhaled COPD agent launched in Japan

Topokine Therapeutics initiates phase II study of XAF-5 gel

Phase III SYNERGY trial of custirsen recommended to continue

European approval for Kadcyla

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...